1. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). (December 2019) Authors: Risi, Emanuela; Biagioni, Chiara; Benelli, Matteo; Migliaccio, Ilenia; McCartney, Amelia; Bonechi, Martina; Guarducci, Cristina; Hilbers, Florentine; Di Cosimo, Serena; Huober, Jens; Romagnoli, Dario; Boccalini, Giulia; Vitale, Stefania; Sotiriou, Christos; Biganzoli, Laura; Di Leo, Angelo; Malor... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. (February 2021) Authors: Migliaccio, Ilenia; Bonechi, Martina; McCartney, Amelia; Guarducci, Cristina; Benelli, Matteo; Biganzoli, Laura; Di Leo, Angelo; Malorni, Luca Journal: Cancer treatment reviews Issue: Volume 93(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. (December 2018) Authors: Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo; Biagioni, Chiara; Boccalini, Giulia; Romagnoli, Dario; Verardo, Roberto; Schiff, Rachel; Osborne, C.; De Angelis, Carmine; Di Leo, Angelo; Malorni, Luca; Migliaccio, Ilenia Journal: NPJ breast cancer Issue: Volume 4(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗